2268 Stock Overview
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
WuXi XDC Cayman Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$24.55 |
| 52 Week High | HK$29.00 |
| 52 Week Low | HK$14.08 |
| Beta | 0 |
| 11 Month Change | 1.45% |
| 3 Month Change | 29.35% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 20.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2268 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -1.6% | -7.1% | -0.6% |
| 1Y | n/a | -58.3% | 9.6% |
Return vs Industry: Insufficient data to determine how 2268 performed against the Hong Kong Life Sciences industry.
Return vs Market: Insufficient data to determine how 2268 performed against the Hong Kong Market.
Price Volatility
| 2268 volatility | |
|---|---|
| 2268 Average Weekly Movement | 10.5% |
| Life Sciences Industry Average Movement | 12.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2268 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2268's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1,496 | Jimmy Li | wuxixdc.com |
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services.
WuXi XDC Cayman Inc. Fundamentals Summary
| 2268 fundamental statistics | |
|---|---|
| Market cap | HK$29.42b |
| Earnings (TTM) | HK$638.57m |
| Revenue (TTM) | HK$3.00b |
46.1x
P/E Ratio9.8x
P/S RatioIs 2268 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2268 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.80b |
| Cost of Revenue | CN¥1.93b |
| Gross Profit | CN¥865.49m |
| Other Expenses | CN¥270.94m |
| Earnings | CN¥594.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 30.96% |
| Net Profit Margin | 21.27% |
| Debt/Equity Ratio | 0.8% |
How did 2268 perform over the long term?
See historical performance and comparison